@article{3187450,
    title = "Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell
Lung Cancer: Incidence, Significance and Implications for Treatment",
    author = "Linardou, Helena and Kotoula, Vassiliki and Kouvatseas, George and and Mountzios, Giannis and Karavasilis, Vasilios and Samantas, Epaminondas and and Kalogera-Fountzila, Anna and Televantou, Despina and Papadopoulou, and Kyriaki and Mavropoulou, Xanthipi and Daskalaki, Emily and Zaramboukas, and Thomas and Efstratiou, Ioannis and Lampaki, Sofia and Rallis, Grigorios and and Res, Eleni and Syrigos, Konstantinos N. and Kosmidis, Paris A. and and Pectasides, Dimitrios and Fountzilas, George",
    journal = "Cancer Genomics & Proteomics",
    year = "2019",
    volume = "16",
    number = "6",
    pages = "531-541",
    publisher = "INT INST ANTICANCER RESEARCH",
    issn = "1109-6535, 1790-6295",
    doi = "10.21873/cgp.20155",
    keywords = "KRAS; EGFR; mutations; platinum-based chemotherapy; NSCLC",
    abstract = "Background/Aim: KRAS mutations are reported in 20-25% of non-small cell
lung cancer (NSCLC) and their prognostic role is unclear. We studied
KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods:
KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients
(diagnosed September 1998 -June 2013) and associated with
clinicopathological parameters. Outcome comparisons were performed in
288 patients receiving first line treatment. Results: Most patients were
male (78.6%), >60 years old (63.9%), current smokers (51.1%), with
adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in
10.7% and 16.6% of all histologies, respectively, and in 14.9% and
21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status
was an independent negative prognostic factor for overall survival (OS,
p=0.016). KRAS mutations conferred 80% increased risk of death in
patients receiving first-line treatment (p=0.002). Conclusion: The
presence of KRAS mutations is an independent negative prognosticator
among Greek NSCLC patients and an independent response predictor to
first line treatment."
}